Cancer Targeted Technology LLC has disclosed conjugates comprising a glutamate carboxypeptidase 2 (FOLH1; NAALAD1; PSMA) targeting ligand covalently linked to a therapeutic or diagnostic agent through a linker reported to be useful for the treatment of prostate cancer.
Cholangiocarcinoma includes several biliary malignant tumors that have poor prognosis. Post-translational modifications in proteins lead to abnormal protein dynamics and disturbances that may cause pathology.
Merkel cell carcinoma (MCC) is an aggressive neuroendocrine skin cancer with a high mortality rate and characterized by frequent local recurrences and metastases. To identify compounds that could be repurposed to treat MCC, National Institutes of Health (NIH) researchers performed a high-throughput cell viability screen of 3,908 small molecules.
Researchers from Vicero Inc. have developed a Vincobody platform, which allows for design of novel proprietary VHH antibody fragments that possess the efficacy of dual checkpoint blockade while mitigating the toxicity limitations of current monoclonal antibody therapies.
Histone deacetylase 3 (HDAC3) is involved in transcriptional regulation, phosphorylation and the inhibition of tumor suppressor genes. Its upregulation in several types of tumors, such as colorectal, prostate, breast and ovarian cancers, among others, makes it a potential therapeutic target in cancer.
Prelude Therapeutics Inc. has disclosed phosphatidylinositol 3-kinase α (PI3Kα) (H1047R mutant) inhibitors reported to be useful for the treatment of cancer, PIK3CA-related overgrowth spectrum and more.
Esophageal cancer, particularly esophageal squamous cell carcinoma (ESCC), is one of the most prevalent digestive malignancies, with a 5-year survival rate of only 20%. Although some cancer immunotherapies based on immune checkpoint inhibitors (ICIs) have shown promise for ESCC, only a minority of patients actually benefit from ICI therapy.
RSS
